OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI® Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion™ ADC enabling technologies.

Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI’s novel Obrion™ ADC enabling technologies(GlycOBI® and GlycOBI DUO®).

HOMEWhat’s NewNewsOBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI® Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion™ ADC enabling technologies

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2026.Apr.09

OBI Presents Obrion™ ADC Technologies at AntibodyChina 2026 in Shanghai Highlighting Scalable Manufacturing and Bispecific Dual-Payload Design